Drug Type Diagnostic radiopharmaceuticals, Radionuclide Drug Conjugates (RDC) |
Synonyms 99mTc-trofolastat, Technetium Tc 99M Trofolastat Chloride, 99MTC-MIP1404 + [3] |
Target |
Mechanism PSMA inhibitors(Prostate-specific membrane antigen inhibitors), SPECT(Single-photon emission-computed tomography enhancers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC40H42N10O23Tc |
InChIKeySEMUBPUAWVZHAS-INZTZQCYSA-F |
CAS Registry1333204-77-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Phase 3 | US | 01 Dec 2015 | |
Prostatic Cancer | Phase 3 | CA | 01 Dec 2015 | |
Contrast agents | Phase 3 | - | - | |
Contrast agents | Phase 3 | - | - | |
Pachyonychia Congenita | Phase 2 | US | 01 Aug 2012 | |
Pachyonychia Congenita | Phase 2 | BE | 01 Aug 2012 | |
Pachyonychia Congenita | Phase 2 | CZ | 01 Aug 2012 | |
Pachyonychia Congenita | Phase 2 | HU | 01 Aug 2012 | |
Pachyonychia Congenita | Phase 2 | IT | 01 Aug 2012 | |
Pachyonychia Congenita | Phase 2 | NL | 01 Aug 2012 |
Phase 2 | 105 | wungihbubq(ijqjjrbtlk) = qggqunqpvd leulszamgu (zgzbgxwiog ) View more | Positive | 01 Sep 2017 |